ANDA 62123, held by Wyeth Ayerst. Erythromycin Ethylsuccinate.
As of Nov 16, 2026, ANDA 62123 (Wyamycin E), held by Wyeth Ayerst, was not approved, with 0 approved supplements and 0 published complete response letters.
| Wyamycin EEQ 400MG BASE/5ML · suspension;oral | Erythromycin Ethylsuccinate | Discontinued |
| Wyamycin EEQ 200MG BASE/5ML · suspension;oral | Erythromycin Ethylsuccinate | Discontinued |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. Drugs@FDA and FDA complete response letters